Giraudo Lidia, Gammaitoni Loretta, Cangemi Michela, Rotolo Ramona, Aglietta Massimo, Sangiolo Dario
Department of Oncology, University of Torino, Turin, Italy.
Laboratory of Medical Oncology, Experimental Cell Therapy, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Turin, Italy.
Immunotherapy. 2015;7(9):999-1010. doi: 10.2217/imt.15.61. Epub 2015 Aug 27.
Cytokine-induced killer (CIK) cells are ex vivo expanded T lymphocytes endowed with potent MHC-independent antitumor activity. CIK cells are emerging as promising therapeutic approach in the field of cancer adoptive immunotherapy, with biologic features favoring their transferability into clinical applications. Aim of this review is to present the biologic characteristic of CIK cells, discussing the main preclinical findings and initial clinical applications in the field of solid tumors.
细胞因子诱导的杀伤细胞（CIK）是在体外扩增的T淋巴细胞，具有强大的非主要组织相容性复合体（MHC）依赖性抗肿瘤活性。CIK细胞正在成为癌症过继性免疫治疗领域一种有前景的治疗方法，其生物学特性有利于它们转化为临床应用。本综述的目的是介绍CIK细胞的生物学特性，讨论实体瘤领域的主要临床前研究结果和初步临床应用。
